Key facts
- Epion Therapeutics’s last known valuation is $55.5M (Sep 2022).
- It has raised $59.2M; the latest was Later Stage VC ($18.5M) in Sep 2025.
- Notable investors include AXA Investment Managers, 7G Bioventures, New World Angels.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Epion Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Epion Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Epion Therapeutics
Provider of medical devices designed to develop an innovative treatment for an ectatic corneal disease that can bring early intervention. The company's devices help to overcome the weakened cornea, the proteins that make up the cornea can be strengthened by chemically cross-linking them and treat keratoconus without disrupting the epithelium, enabling patients to avail of enhanced vision that is available in a wide range for the treatment of eye diseases.
- Sector
- Healthcare
- HQ
- Burlington, MA, United States
- Founded
- 2012
- Employees
- 5
- Website
- epiontx.com/
- Ownership
- Privately Held (backing)
Epion Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Epion Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Epion Therapeutics in its N-PORT filings yet. We sweep new filings monthly.